Analyst Reco. Verve Therapeutics, Inc.

Equities

VERV

US92539P1012

Market Closed - Nasdaq Other stock markets 04:00:08 2024-05-17 pm EDT			5-day change	1st Jan Change
5.965 ^USD	-6.50%		-0.75%	-57.21%

May. 16	Verve Therapeutics CFO Andrew Ashe Executes Purchase of 76,000 Shares of Common Stock; Shares Jump Premarket	MT
May. 08	Verve Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Verve Therapeutics CFO Andrew Ashe Executes Purchase of 76,000 Shares of Common Stock; Shares Jump Premarket	May. 16	MT
Stifel Cuts Price Target on Verve Therapeutics to $40 From $56, Maintains Buy Rating	Apr. 03	MT
Rate Outlooks Push Exchange-Traded Funds, Equity Futures Higher Pre-Bell Wednesday	Nov. 29	MT
Guggenheim Adjusts Price Target on Verve Therapeutics to $55 From $56, Maintains Buy Rating	23-08-15	MT
Canaccord Genuity Starts Verve Therapeutics at Buy With $29 Price Target	23-04-13	MT
Credit Suisse Lowers Verve Therapeutics' Price Target to $32 From $37, Maintains Neutral Rating	23-03-03	MT
Cantor Fitzgerald Initiates Verve Therapeutics at Neutral With $21 Price Target	23-02-01	MT
Goldman Sachs Initiates Verve Therapeutics at Sell With $13 Price Target	22-12-15	MT
RBC Cuts Price Target on Verve Therapeutics to $35 From $42, Maintains Outperform, Speculative Risk Rating	22-11-08	MT
Credit Suisse Starts Verve Therapeutics at Neutral with $48 Price Target	22-10-06	MT
Stifel Raises Verve Therapeutics to Buy From Hold, Price Target to $56 From $32	22-08-25	MT
Guggenheim Adjusts Price Target for Verve Therapeutics to $56 From $64, Maintains Buy Rating	22-07-25	MT
BMO Capital Raises Verve Therapeutics' Price Target to $62 From $48, Maintains Outperform Rating, Shares Climb 21%	22-07-18	MT
Verve Therapeutics Shares Rise After BMO Capital Initiates Coverage at Outperform	22-06-17	MT
BMO Capital Initiates Verve Therapeutics at Outperform With $48 Price Target	22-06-17	MT
Guggenheim Cuts Verve Therapeutics Price Target to $64 From $84, Maintains Buy Rating	22-03-21	MT
Stifel Adjusts Verve Therapeutics' Price Target to $34 From $58, Reiterates Hold Rating	22-03-15	MT
RBC Initiates Verve Therapeutics at Outperform-Speculative Risk, Sees 'A Great Entry Point,' Sets Price Target at $42	22-02-18	MT
VERVE THERAPEUTICS : Stifel Starts Verve Therapeutics at Hold With $58 Price Target	21-09-24	MT
VERVE THERAPEUTICS : William Blair Starts Verve Therapeutics at Outperform	21-07-12	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Verve Therapeutics, Inc.

Equities

VERV

US92539P1012

Analyst Reco.

Filters